# A Single Ascending Dose Study To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of AZD9567.

> **NCT02512575** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 72 (actual)

## Conditions studied

- Safety
- Tolerability
- Pharmacokinetics
- Pharmacodynamics
- Healthy Subjects
- Rheumatoid Arthritis

## Interventions

- **DRUG:** AZD9567 Monohydrat
- **DRUG:** Placebo oral suspension/ Placebo capsule
- **DRUG:** Prednisolone

## Key facts

- **NCT ID:** NCT02512575
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-18
- **Primary completion:** 2016-09-26
- **Final completion:** 2016-09-26
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2018-10-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02512575

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02512575, "A Single Ascending Dose Study To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of AZD9567.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02512575. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*